Pharma channel feed

Fi­nal­ly sat­is­fied with Oc­u­lar's man­u­fac­tur­ing set­up, FDA ap­proves eye drug/de­vice Dex­ten­za

7 years ago

J&J pays $500M in cash to grab rights to a new star can­cer drug at ar­genx

7 years ago
R&D

Spot­light on drug pric­ing could be cat­a­lyst for change in US biosim­i­lar land­scape

7 years ago
R&D

FDA to fol­low EMA with move from Lon­don to Am­s­ter­dam

7 years ago

Cat­a­lyst Phar­ma's LEMS drug Fir­dapse wins FDA nod, as reg­u­la­tors keep the ap­proval en­gine run­ning at record speed

7 years ago

FDA stamps fast OK on Astel­las' pi­o­neer­ing FLT3 AML drug gilter­i­tinib, ex­pand­ing on a record year for new ap­provals

7 years ago

No­var­tis HQ is pulling up its roots in the UK and mov­ing to a new biotech cam­pus in Lon­don

7 years ago

FDA warns in­ves­ti­ga­tor for vi­o­lat­ing clin­i­cal hold

7 years ago

In the lat­est re­verse merg­er, Vi­en­na's Ar­sa­nis serves as ve­hi­cle for X4 Phar­ma's Nas­daq list­ing

7 years ago

Glob­al syn­di­cate backs $400M ge­nomics R&D play in Ire­land as WuXi NextCODE ex­tends its reach in­to Eu­rope

7 years ago
Financing
R&D

Trump pro­pos­al ta­pers Medicare pro­tec­tion for cer­tain drugs if drug­mak­ers don't tem­per pric­ing

7 years ago

Shat­ter­ing an old record, FDA quick­ly OKs pi­o­neer­ing, site-ag­nos­tic can­cer drug larotrec­tinib from Loxo and Bay­er

7 years ago

Af­ter falling off a cliff, Edge Ther­a­peu­tics pro­vides can­cer-fo­cused PDS Biotech a re­verse merg­er on­to Nas­daq

7 years ago

Play­ing a hot hand in can­cer R&D, Pfiz­er scores its 4th drug ap­proval in just 2 months

7 years ago

Pfiz­er wants to reel back con­tri­bu­tions to Hyde-Smith af­ter her re­marks about ‘pub­lic hang­ing’ spark con­tro­ver­sy

7 years ago

Roche ties up again with As­cle­tis — this time on a com­mer­cial part­ner­ship for hep B drug

7 years ago

No­var­tis banks on the promise of dig­i­tal ther­a­peu­tics in the man­age­ment of chron­ic dis­or­ders

7 years ago

Clozel hands over a ri­val to PTC’s con­tro­ver­sial steroid de­flaza­cort — now in a piv­otal study for Duchenne MD

7 years ago

So­bi’s $50M bet on a rare dis­ease drug pays off with a quick FDA nod

7 years ago

FDA opts to nail down REMS plan for Sage's land­mark post­par­tum de­pres­sion drug, de­lays fi­nal de­ci­sion

7 years ago

As pow­er shifts hands in Wash­ing­ton, a top an­a­lyst pre­dicts an un­avoid­able war over ris­ing drug prices

7 years ago

FDA works to re­duce dog test­ing in drug de­vel­op­ment

7 years ago

Leo Phar­ma lines up an op­tion to buy Bridge­Bio's Pelle­Pharm and its PhI­II rare skin can­cer drug

7 years ago

While con­tro­ver­sy over Brex­it reach­es full boil, a phar­ma trade group sees the up­side in a draft deal

7 years ago
R&D
First page Previous page 282283284285286287288 Next page Last page
A service from the Financial Times